---
title: "Top Executive Doubles Down on Greenwich LifeSciences With Fresh Insider Buy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294443392.md"
description: "Greenwich LifeSciences CEO and CFO Snehal Patel purchased $29,555 worth of shares on July 30, 2026, signaling confidence. This follows regulatory approvals to expand the FLAMINGO-01 breast cancer trial globally, doubling enrollment. An analyst raised the price target due to increased commercial opportunity and trial success probability, despite a -39% YTD stock decline and a 'Strong Sell' technical signal."
datetime: "2026-07-31T02:05:50.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294443392.md)
  - [en](https://longbridge.com/en/news/294443392.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294443392.md)
generator: "portal-rs"
---

# Top Executive Doubles Down on Greenwich LifeSciences With Fresh Insider Buy

New insider activity at Greenwich LifeSciences ( (GLSI) ) has taken place on July 30, 2026.

Greenwich LifeSciences just saw a notable insider move as CEO and CFO Snehal Patel purchased 2,200 shares of the company’s stock in a single transaction valued at $29,555. This buy signals increased executive confidence in the company’s future, as a top leader commits personal capital to Greenwich LifeSciences at this scale.

Greenwich LifeSciences shares moved on news that regulators in the U.K., FDA, and EMA approved expanding the FLAMINGO-01 breast cancer trial to include all HLA patient types across nearly 200 sites, effectively more than doubling enrollment and broadening the potential market for GP2. An analyst raised the price target mainly because this unified global protocol and larger, statistically stronger study design significantly increase the therapy’s commercial opportunity and probability of trial success while the company maintains a manageable cash burn and explores non-dilutive funding options.

**More about Greenwich LifeSciences**

**YTD Price Performance:** -39.08%

**Average Trading Volume:** 159,420

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $197.4M

### Related Stocks

- [GLSI.US](https://longbridge.com/en/quote/GLSI.US.md)

## Related News & Research

- [EMA clears Greenwich Lifesciences’ commercially manufactured GP2 for use in FLAMINGO-01 trial in Europe](https://longbridge.com/en/news/292180524.md)
- [BUZZ-Greenwich LifeSciences rises after EMA update for breast cancer drug](https://longbridge.com/en/news/292191603.md)
- [BridgeBio says FDA reviews NDA for infigratinib in achondroplasia](https://longbridge.com/en/news/298419562.md)
- [Opus Genetics reports positive Phase 1/2 low-dose Cohort 1 data for OPGx-BEST1 gene therapy in BEST1 retinal disease](https://longbridge.com/en/news/298445913.md)
- [Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event | ZBIO Stock News](https://longbridge.com/en/news/298308343.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**